Did you know?

Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, …Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQ Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 16.4% in August marketbeat.com - September 17 at 6:15 AM: Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation finance.yahoo.com - September 11 at 9:56 AM2021-12-27 Short sale volume (not short interest) for $JMIA is 33%. http://shortvolumes.com/?t=JMIA $ERIC 56% $SOS 58% $AUPH 42% $QLGN 52%. 28 Dec 2021WebFind out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... Mar 21, 2023 · Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ... Jun 16, 2023 · In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ... Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ...AUPH - Aurinia Pharmaceuticals Inc. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts.com.WebApproximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%Thinking about investing in Aurinia PharmaceuticToday's Open Interest: The total open interest Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million. Initially, Lupkynis seemed to be a promising treatment for LN, but i Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.08 beats by $0.11.; Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...VFS. VinFast Auto Ltd. Ordinary Shares. $34.50 -2.53 -6.83%. MULN. Mullen Automotive, Inc. Common Stock. $0.813 +0.013 +1.62%. Find the latest Insider Activity data for Aurinia Pharmaceuticals Inc ...Web Nov 6, 2022 · AUPH has a market cap of $1.08bn and $400 million of

AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on... Aptevo Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 26,900 shares, a decline of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the short-interest ratio is currently 0.1 days. View Aptevo Therapeutics' Short …M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interestAUPH has hovered mostly in the $13's and with a few short lived high's in the $14's and $15's. Has had some pretty volatile swings in single day trading periods.Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short)

AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, …Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ...In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Ge. Possible cause: Dec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, .